What were the key takeaways from Alkermes's earnings call?

What guidance did Alkermes's management provide for the next earnings period?

What is Alkermes's gross profit margin?

What is the market's earnings forecast for Alkermes next quarter?

What does Alkermes do and what are its main business segments?

What factors drove the changes in Alkermes's revenue and profit?

Did Alkermes beat or miss consensus estimates last quarter?

What were the key takeaways from Alkermes’s earnings call?

- **Acquisition of Avadel**: Adds LUMRYZ to diversify portfolio, with 2025 revenue of $265–$275 million.
- **Revenue Growth**: Q3 proprietary products up 16% to $317.4 million; full-year guidance raised to $1.43–$1.49 billion.
- **Pipeline Momentum**: Alixorexton NT1 Phase II data positive; NT2 data due in November with potential Phase III start in Q1 2026.
- **Product Performance**: VIVITROL, ARISTADA, and LYBALVI all exceed prior guidance, with LYBALVI TRx growth 25% YoY.
- **Financial Strength**: Q3 GAAP net income $82.8 million; EBITDA $96.9 million, with strong cash position ($1.14 billion).

**【CEO Opening Remarks】**
- Announced the proposed acquisition of Avadel Pharmaceuticals, adding LUMRYZ (FDA-approved oxybate) to diversify the portfolio and enter the sleep medicine market. Expected 2025 revenue contribution: $265–$275 million.
- Highlighted progress in the orexin receptor agonist pipeline, including alixorexton Phase II data in narcolepsy type 1 (NT1) and upcoming NT2 data in November.
- Raised full-year 2025 guidance: Total revenues $1.43–$1.49 billion, GAAP net income $230–$250 million, EBITDA $270–$290 million.

**【CFO Financial Commentary】**
- Q3 2025 total revenues: $394.2 million (16% YoY growth in proprietary products to $317.4 million).
- Gross-to-net favorability: $8 million (VIVITROL) and $5 million (ARISTADA) due to Medicaid utilization.
- R&D expenses: $81.7 million (investing in alixorexton Phase II and new orexin candidates ALKS 4510/7290).
- Q4 2025 proprietary product net sales guidance: $300–$320 million.

**【Commercial Update】**
- **VIVITROL**: Q3 net sales $121.1 million, full-year guidance raised to $460–$470 million. Driven by alcohol dependence market growth.
- **ARISTADA**: Q3 net sales $98.1 million, full-year guidance $360–$370 million. New-to-brand prescriptions and prescriber breadth increasing.
- **LYBALVI**: Q3 net sales $98.2 million (32% YoY growth), full-year guidance $340–$350 million. TRx growth 25% YoY, gross-to-net 28%.

**【Q&A Highlights】**
- **LYBALVI**: Strong TRx growth (25% YoY) due to expanded sales force. Q4 gross-to-net expected to rise slightly, but full-year guidance maintained.
- **Alixorexton NT2**: Phase II data expected in November; potential Phase III launch Q1 2026. Focus on dose response and safety in NT2 vs. NT1.
- **Policy Impact**: Medicaid utilization dynamics drove Q3 favorability, but no additional benefits expected in Q4.
- **Pipeline Expansion**: ALKS 4510/7290 Phase I studies progressing; no-salt oxybate (valiloxybate) in early development.

Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

ALKS

ALKS fundamentals

You can ask Aime